What is PrimaDiag?
Founded in 2007, PrimaDiag operates at the intersection of robotics, computer science, and life sciences. The company specializes in the development of compact, high-precision robotic platforms designed to streamline complex laboratory workflows. Its flagship ACSIA product line, introduced in 2014, serves as a cornerstone for modern research facilities, enabling the rapid automation of critical protocols such as PCR preparation, nucleic acid purification, and Next-Generation Sequencing (NGS) execution. Through the integration of its proprietary PrimaControllerII software, PrimaDiag provides researchers with robust, cost-effective solutions that minimize manual intervention while maximizing throughput and reproducibility in biological analysis.
How much funding has PrimaDiag raised?
PrimaDiag has raised a total of $423K across 1 funding round:
Angel/Seed
$423K
Angel/Seed (2009): $423K with participation from Investessor BA
Key Investors in PrimaDiag
Investessor BA
Investessor is a prominent French business angel association that connects promising entrepreneurs with a vast network of experienced investors to foster economic growth and innovation.
What's next for PrimaDiag?
With this recent infusion of capital, PrimaDiag is strategically positioned to scale its manufacturing capabilities and expand its international footprint. The company is expected to focus on enhancing its software ecosystem to support increasingly complex genomic workflows, thereby addressing the evolving needs of clinical and research laboratories. By prioritizing R&D in robotic precision and protocol versatility, PrimaDiag aims to maintain its competitive edge, ensuring that its automation platforms remain the standard for efficiency in molecular diagnostics and biotechnology research. Future growth will likely center on strategic partnerships and the continued optimization of its automated hardware-software integration.
See full PrimaDiag company page
